Logo image
Advances in the management of brain metastases from cancer of unknown primary
Journal article   Peer reviewed

Advances in the management of brain metastases from cancer of unknown primary

Elie Rassy, Mario Zanaty, Fares Azoury and Nicholas Pavlidis
Future oncology (London, England), Vol.15(23), pp.2759-2768
08/01/2019
DOI: 10.2217/fon-2019-0108
PMID: 31385529

View Online

Abstract

Cancer of unknown primary accounts for 3-5% of all cancers for which an adequate investigation does not identify the primary tumor. The particular subset of brain metastasis in cancer of unknown primary (BMCUP) is a clinical challenge that lacks standardized diagnostic and therapeutic options. It is diagnosed predominantly in male patients in the sixth decade of age with complaints of headache, neurological dysfunction, cognitive and behavioral disturbances and seizures. The therapeutic approach to patients with BMCUP relies on local control and systemic treatment. Surgery or stereotactic radiosurgery and/or whole brain radiation therapy seems to be the cornerstone of the treatment approach to BMCUP. Systemic therapy remains essential as cancers of unknown primary are conceptually metastatic tumors. The benefits of chemotherapy were disappointing whereas those of targeted therapies and immune checkpoint inhibitors remain to be evaluated. In this Review, we address the advances in the diagnosis and treatment of BMCUP.
Oncology Life Sciences & Biomedicine Science & Technology

Details

Logo image